title: Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.
abstract: OBJECTIVE
  In the few studies to evaluate antimuscarinics for overactive bladder (OAB) in men, safety has been the primary focus. In OAB efficacy trials, subject populations have been predominantly female and patient-reported outcomes (PROs) have been assessed only recently. We present a post hoc analysis of PRO-based findings from the subset of men (without presumed bladder outlet obstruction [BOO]) from two large, independent, open-label trials of solifenacin.
  
  
  METHODS
  Subjects with OAB for > or =3 months received flexibly dosed solifenacin for 12 weeks. At baseline and 4-week intervals, subjects completed the Patient Perception of Bladder Condition (PPBC) and Overactive Bladder Questionnaire (OAB-q). In one study, subjects also completed 3-day bladder diaries. At baseline, mean PPBC scores were similar in both studies and indicative of moderate-to-severe problems.
  
  
  RESULTS
  After 12 weeks of solifenacin, mean PPBC scores improved significantly (p < 0.0001); values were suggestive of minor-to-moderate problems. Mean scores on the OAB-q were also significantly improved after solifenacin (p values < or =0.001). In men without presumed BOO, solifenacin significantly improved PRO measures of symptom bother, health-related quality of life, and overall perception of bladder problems.
  
  
  CONCLUSIONS
  Results from these two studies support the use of solifenacin as a well-tolerated and efficacious treatment option for providing symptom relief in men with OAB without BOO.
authors.affiliation: Department of Urology, Weill Cornell Medical College, New York, New York 10065, USA. kaplans@med.cornell.edu
authors.forename: Steven A
authors.initials: SA
authors.lastname: Kaplan
authors.forename: Evan R
authors.initials: ER
authors.lastname: Goldfischer
authors.forename: William D
authors.initials: WD
authors.lastname: Steers
authors.forename: Marc
authors.initials: M
authors.lastname: Gittelman
authors.forename: Masakazu
authors.initials: M
authors.lastname: Andoh
authors.forename: Sergio
authors.initials: S
authors.lastname: Forero-Schwanhaeuser
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011812:Quinuclidines / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014554:Urination / Q000187:drug effects
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate